JP6385732B2 - 免疫応答制御剤 - Google Patents

免疫応答制御剤 Download PDF

Info

Publication number
JP6385732B2
JP6385732B2 JP2014133377A JP2014133377A JP6385732B2 JP 6385732 B2 JP6385732 B2 JP 6385732B2 JP 2014133377 A JP2014133377 A JP 2014133377A JP 2014133377 A JP2014133377 A JP 2014133377A JP 6385732 B2 JP6385732 B2 JP 6385732B2
Authority
JP
Japan
Prior art keywords
mir
immune response
hsa
nucleic acid
stimulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014133377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016011272A5 (enExample
JP2016011272A (ja
Inventor
秀光 北村
秀光 北村
紹信 武冨
紹信 武冨
陽介 大野
陽介 大野
淳矢 大竹
淳矢 大竹
聖 寺田
聖 寺田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hokkaido University NUC
Original Assignee
Hokkaido University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hokkaido University NUC filed Critical Hokkaido University NUC
Priority to JP2014133377A priority Critical patent/JP6385732B2/ja
Publication of JP2016011272A publication Critical patent/JP2016011272A/ja
Publication of JP2016011272A5 publication Critical patent/JP2016011272A5/ja
Application granted granted Critical
Publication of JP6385732B2 publication Critical patent/JP6385732B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014133377A 2014-06-27 2014-06-27 免疫応答制御剤 Active JP6385732B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014133377A JP6385732B2 (ja) 2014-06-27 2014-06-27 免疫応答制御剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014133377A JP6385732B2 (ja) 2014-06-27 2014-06-27 免疫応答制御剤

Publications (3)

Publication Number Publication Date
JP2016011272A JP2016011272A (ja) 2016-01-21
JP2016011272A5 JP2016011272A5 (enExample) 2018-03-01
JP6385732B2 true JP6385732B2 (ja) 2018-09-05

Family

ID=55228217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014133377A Active JP6385732B2 (ja) 2014-06-27 2014-06-27 免疫応答制御剤

Country Status (1)

Country Link
JP (1) JP6385732B2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6566612B2 (ja) * 2014-06-27 2019-08-28 国立大学法人北海道大学 免疫体質又は免疫応答型を判定するためのバイオマーカー及び免疫応答型制御剤
CN108853132A (zh) * 2018-05-22 2018-11-23 深圳先进技术研究院 一种miR-340调控IL-17A表达的用途
US20220177967A1 (en) * 2019-03-08 2022-06-09 Edward E. Winger, M.D., Professional Corporation Reagents, methods and kits for identifying pregnant human beings at risk for placental bed disorder(s)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2475372B2 (en) * 2009-09-10 2020-10-21 Velin-Pharma A/S Method for the preparation of micro-rna and its therapeutic application
US20140080894A1 (en) * 2011-03-02 2014-03-20 David L. McElligott Enhanced biodistribution of oligomers
US9725721B2 (en) * 2012-09-26 2017-08-08 Mirrx Therapeutics Oligomers with improved off-target profile
CA2892529C (en) * 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna

Also Published As

Publication number Publication date
JP2016011272A (ja) 2016-01-21

Similar Documents

Publication Publication Date Title
JP5291129B2 (ja) 細胞および／または組織および／または疾患フェーズ特異的な薬剤の製造方法
JP6175103B2 (ja) 免疫反応を増加させるための方法
JP7602702B2 (ja) 寛容性を誘導するための生体分子の細胞内送達
US11896616B2 (en) Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
US11186825B2 (en) Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1
Pollard et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines
Ebner et al. Microglial activation milieu controls regulatory T cell responses
JP2024001342A (ja) 寛容性を誘導するための生体分子の細胞内送達
AU2016251687C1 (en) RNA containing composition for treatment of tumor diseases
Heo et al. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells
Reyes-Sandoval et al. CpG methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses
JP2013535969A5 (enExample)
WO2012093258A2 (en) Treatment and screening
Zhao et al. Chitosan nanovaccines as efficient carrier adjuvant system for IL-12 with enhanced protection against HBV
EP3301179B1 (en) Immunostimulating oligonucleotide complex
Creusot et al. A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice
Gu et al. Dectin-1 controls TSLP-induced Th2 response by regulating STAT3, STAT6, and p50-RelB activities in dendritic cells
JP6385732B2 (ja) 免疫応答制御剤
Goriely et al. Interleukin‐12 family members and type I interferons in Th17‐mediated inflammatory disorders
JP2022023136A (ja) Ｔ細胞の拡張及び活性化の方法
US11369663B2 (en) Detection of CD5 and methods and compositions for modulating CD5
WO2020150394A1 (en) Regulation of a foreign body response
Xie et al. Mesencephalic astrocyte-derived neurotrophic factor supports hepatitis B virus-induced immunotolerance
JP6566612B2 (ja) 免疫体質又は免疫応答型を判定するためのバイオマーカー及び免疫応答型制御剤
Ichim et al. A novel method of modifying immune responses by vaccination with lipiodol-siRNA mixtures

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170627

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20170627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180710

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180808

R150 Certificate of patent or registration of utility model

Ref document number: 6385732

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250